| Symbol
| SPRY4
| contributors: mct/npt/pgu - updated : 22-10-2015
|
| HGNC name
| sprouty homolog 4 (Drosophila)
|
| HGNC id
| 15533
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
|
| loss of function
| |
epigenetic silencing and loss-of-function mutations in progenitor cells could lead to carcinogenesis | | tumoral
|
|
| --low
|
| |
in prostate cancer by DNA methylation and this decreased expression may contribute to increased cell migration | |
| Susceptibility
|
to testicular germ cell tumors (TGCT) to congenital Hypogonadotropic Hypogonadism |
| Variant & Polymorphism
other
| rs4324715 and rs6897876 increasing the risk of testicular germ cell tumors (TGCT)  |
| 
|
Candidate gene
Marker
| Therapy target
| pharmacogenomics target in the fields of oncology and regenerative medicine | |
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | lung | | |
| may have efficacy in the treatment of non-small cell lung cancer | | miscelleaneous | vascular | | |
| targeting SPRY4 may be exploited as a target in anti-angiogenesis therapies |
| | |